ATNT-08CB-017: A PHASE 1/2 TRIAL OF BEVACIZUMAB PLUS TPI 287, A NOVEL BRAIN PENETRABLE ANTI-MICROTUBULE AGENT, IN PATIENTS WITH RECURRENT GLIOBLASTOMA NAÏVE TO ANTI-ANGIOGENIC THERAPY
Saved in:
Published in | Neuro-oncology (Charlottesville, Va.) Vol. 17; no. suppl 5; pp. v11.4 - v12 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Oxford University Press
01.11.2015
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
ISSN: | 1522-8517 1523-5866 |
---|---|
DOI: | 10.1093/neuonc/nov205.08 |